CDTX vs. DYN, ANIP, BGM, OCUL, CALT, AMPH, ETNB, AUPH, GYRE, and MLYS
Should you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include Dyne Therapeutics (DYN), ANI Pharmaceuticals (ANIP), Qilian International Holding Group (BGM), Ocular Therapeutix (OCUL), Calliditas Therapeutics AB (publ) (CALT), Amphastar Pharmaceuticals (AMPH), 89bio (ETNB), Aurinia Pharmaceuticals (AUPH), Gyre Therapeutics (GYRE), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry.
Cidara Therapeutics vs.
Dyne Therapeutics (NASDAQ:DYN) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk.
Dyne Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.
Dyne Therapeutics currently has a consensus price target of $47.25, suggesting a potential upside of 301.79%. Cidara Therapeutics has a consensus price target of $41.71, suggesting a potential upside of 58.91%. Given Dyne Therapeutics' higher possible upside, equities research analysts clearly believe Dyne Therapeutics is more favorable than Cidara Therapeutics.
Cidara Therapeutics has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks.
96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are owned by institutional investors. 20.8% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 3.9% of Cidara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Cidara Therapeutics received 414 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 77.97% of users gave Dyne Therapeutics an outperform vote while only 70.34% of users gave Cidara Therapeutics an outperform vote.
Dyne Therapeutics has a net margin of 0.00% compared to Cidara Therapeutics' net margin of -289.05%. Dyne Therapeutics' return on equity of -57.46% beat Cidara Therapeutics' return on equity.
In the previous week, Dyne Therapeutics had 7 more articles in the media than Cidara Therapeutics. MarketBeat recorded 11 mentions for Dyne Therapeutics and 4 mentions for Cidara Therapeutics. Dyne Therapeutics' average media sentiment score of 1.45 beat Cidara Therapeutics' score of 0.84 indicating that Dyne Therapeutics is being referred to more favorably in the media.
Summary
Dyne Therapeutics beats Cidara Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Cidara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cidara Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CDTX) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy CDTX Stock Free CDTX Stock Alerts